PHLOJEL® Synergy 3:1
PHLOJEL® Synergy 3:1 is a versatile lecithin organogel designed for transdermal drug delivery. Featuring a unique 3:1 ratio of hydrophilic and organic components, it offers distinct solubility and viscosity for specialized compounding. Ideal for cases needing tailored physical properties to suit individual patient needs.
Features
Balanced Absorption
PHLOJEL® Synergy 3:1 offers a carefully balanced absorption profile, ensuring consistent delivery of active ingredients over time, making it ideal for treatments that require a controlled release.
Enhanced Versatility
The unique 3:1 ratio of hydrophilic to organic components provides increased flexibility in compounding, allowing for a broader range of drug formulations, especially those requiring specific viscosity and solubility characteristics.
Low-Allergenicity
With reduced soy lecithin content compared to some alternatives, PHLOJEL® Synergy 3:1 offers a lower risk of allergic reactions, providing a safer option for sensitive patients.
Ease of Removal
In cases of adverse reactions, the gel can be easily washed off the skin, providing an additional safety net for patient care.
The PHLOJEL® Synergy 3:1 Advantage
PHLOJEL® Synergy 3:1 offers a unique approach to transdermal drug delivery by providing a distinct balance of hydrophilic and organic components. This gel is particularly useful in situations where a more controlled release of medication is needed, or when a specific gel consistency is required to meet the therapeutic needs of the patient. It is ideal for use in conditions that require a steady, prolonged release of the active pharmaceutical ingredient, ensuring consistent therapeutic outcomes.
Balanced Release Profile
Temperature-Responsive Stability
PHLOJEL® Synergy 3:1 ensures a steady and controlled release of medication, making it suitable for conditions requiring prolonged therapeutic effects.
Its thermal responsiveness allows PHLOJEL® Synergy 3:1 to remain stable and effective across a variety of environmental conditions, from cold storage to warmer application environments.
Gentle on Skin
Reduced soy lecithin content lowers the risk of skin reactions, making it a suitable option for patients with sensitivities or allergies.
Alternative Composition
The 3:1 ratio of hydrophilic to organic components offers a different viscosity and solubility profile compared to PHLOJEL® Ultra, providing an alternative solution for specific compounding needs.
Preperation Guide
Learn the best practices when preparing PHLOJEL® Synergy 3:1
FAQ
How does PHLOJEL® Synergy 3:1 differ from PHLOJEL® Ultra?
PHLOJEL® Synergy 3:1 utilizes a unique 3:1 ratio of hydrophilic to organic components, providing a different balance of viscosity and solubility, making it suitable for compounding scenarios that require specific physical properties of the gel.
What types of medications can be compounded with PHLOJEL® Synergy 3:1?
PHLOJEL® Synergy 3:1 is versatile and can be used to compound a wide range of medications, including NSAIDs, hormones, and other pharmaceutical agents, particularly those requiring specific gel consistency.
Is PHLOJEL® Synergy 3:1 suitable for sensitive skin?
Yes, with its reduced soy lecithin content, PHLOJEL® Synergy 3:1 is designed to minimize allergic reactions and is gentle on sensitive skin.
How should PHLOJEL® Synergy 3:1 be stored?
Due to its thermal responsiveness, PHLOJEL® Synergy 3:1 should be stored in a cool, dry place. It remains fluid at low temperatures and solidifies at higher temperatures, maintaining its stability and effectiveness.
Can PHLOJEL® Synergy 3:1 be used for controlled drug release?
Absolutely. The unique composition of PHLOJEL® Synergy 3:1 allows for a balanced and controlled release of medication, ideal for treatments that require consistent therapeutic effects over time.
What is the primary advantage of PHLOJEL® Synergy 3:1 in pharmaceutical compounding?
The primary advantage is its balanced 3:1 composition, which offers enhanced flexibility in creating tailored formulations that require specific viscosity, solubility, and controlled drug release.
